Condition · Neurology
Small Fiber Neuropathy
00
Background biology
Small-fibre injury can occur with diabetes, sarcoidosis, immune disease, genetic disorders or without an identified cause.
01
Evidence-ranked peptides
| Peptide | Use | Evidence |
|---|---|---|
| ARA-290 An investigational erythropoietin-derived peptide studied for neuropathic pain and tissue protection. | Small Fiber Neuropathy moderate | Human5/5 Animal0/5 Safety3/5 3 verified refs |
| Cibinetide Cibinetide is an investigational peptide, analogue or research construct with evidence ranging from mechanistic studies to limited human trials. | Small Fiber Neuropathy weak | Human0/5 Animal0/5 Safety0/5 0 verified refs |
02
Current standard management
conventional medicineManagement targets the underlying cause where possible and uses evidence-based neuropathic-pain care and specialist assessment.
Medical disclaimer —Standard-of-care information is educational only. Do not change or start treatment based on Atlas content. Always consult a qualified clinician for personal medical decisions.
04
Linked mechanisms
biological pathways discussed for this condition- Innate repair receptor signallinglimited
- Inflammation modulationlimited
05
Research gaps
what we don't know yet- ·Confirmatory cibinetide trials
- ·Durability of nerve regeneration
- ·Clinically meaningful pain outcomes
- ·Long-term safety
03
Community observations
No approved community reports for this condition yet. Submit one.
Clinician discussion
Questions you can ask a qualified clinician
- What are the established evidence-based options for this condition?
- What monitoring is appropriate before considering any experimental intervention?
- What long-term safety data exists for peptide-based approaches?
- Are there licensed medicines relevant to my situation?
↳